BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30367117)

  • 1. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
    Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.
    Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR
    PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
    Gasi D; Trapman J
    Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.
    Faisal FA; Sundi D; Tosoian JJ; Choeurng V; Alshalalfa M; Ross AE; Klein E; Den R; Dicker A; Erho N; Davicioni E; Lotan TL; Schaeffer EM
    Eur Urol; 2016 Jul; 70(1):14-17. PubMed ID: 26443432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
    Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
    Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ETS fusion genes in prostate cancer.
    Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
    Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
    Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
    Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
    Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
    Bu H; Narisu N; Schlick B; Rainer J; Manke T; Schäfer G; Pasqualini L; Chines P; Schweiger MR; Fuchsberger C; Klocker H
    Hum Mutat; 2016 Jan; 37(1):52-64. PubMed ID: 26411452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?
    Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N
    Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
    Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
    Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
    Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
    Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
    Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
    PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS gene fusions in prostate cancer.
    Clark JP; Cooper CS
    Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.
    Kim J; Wu L; Zhao JC; Jin HJ; Yu J
    Oncogene; 2014 Oct; 33(44):5183-92. PubMed ID: 24186205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.